Indivior (NASDAQ:INDV) and Inhibitor Therapeutics (OTCMKTS:INTI) Head-To-Head Review

Indivior (NASDAQ:INDV) and Inhibitor Therapeutics (OTCMKTS:INTI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Earnings and Valuation

This table compares Indivior and Inhibitor Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24 billion	3.82	$210.00 million	$1.95	19.92
Inhibitor Therapeutics	N/A	N/A	-$3.30 million	($0.01)	-8.31

Indivior has higher revenue and earnings than Inhibitor Therapeutics. Inhibitor Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Indivior and Inhibitor Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	1	5	1	3.00
Inhibitor Therapeutics	0	0	0	0	0.00

Indivior presently has a consensus target price of $39.33, suggesting a potential upside of 1.27%. Given Indivior’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Indivior is more favorable than Inhibitor Therapeutics.

Profitability

This table compares Indivior and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Inhibitor Therapeutics	N/A	-1,693.49%	-93.89%

Risk & Volatility

Indivior has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.58, indicating that its stock price is 158% less volatile than the S&P 500.

Institutional & Insider Ownership

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Indivior beats Inhibitor Therapeutics on 13 of the 14 factors compared between the two stocks.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.